» Articles » PMID: 35368453

Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs

Abstract

To date, investigations of the microbiota in the lungs of people with Cystic Fibrosis (PWCF) have primarily focused on microbial community composition in luminal mucus, with fewer studies observing the microbiota in tissue samples from explanted lung tissue. Here, we analysed both tissue and airway luminal mucus samples extracted from whole explanted lungs of PWCF and unused donor lungs. We determined if the lung microbiota in end-stage CF varied within and between patients, was spatially heterogeneous and related to localized structural damage. Microbial community composition was determined by Illumina MiSeq sequencing and related to the CF-Computed Tomography (CT) score and features of end-stage lung disease on micro-CT. Ninety-eight CF tissue (n=11 patients), 20 CF luminal mucus (n=8 patients) and 33 donor tissue (n=4 patients) samples were analysed. Additionally, we compared 20 paired CF tissue and luminal mucus samples that enabled a direct "geographical" comparison of the microbiota in these two niches. Significant differences in microbial communities were apparent between the 3 groups. However, overlap between the three groups, particularly between CF and donor tissue and CF tissue and CF luminal mucus was also observed. Microbial diversity was lower in CF luminal mucus compared to CF tissue, with dominance higher in luminal mucus. For both CF and donor tissue, intra- and inter-patient variability in ecological parameters was observed. No relationships were observed between ecological parameters and CF-CT score, or features of end-stage lung disease. The end-stage CF lung is characterised by a low diversity microbiota, differing within and between individuals. No clear relationship was observed between regional microbiota variation and structural lung damage.

Citing Articles

Microbiome-Mucosal Immunity Nexus: Driving Forces in Respiratory Disease Progression.

Park Y, Choi S, Cha Y, Yoon H, Son Y J Microbiol. 2024; 62(9):709-725.

PMID: 39240507 DOI: 10.1007/s12275-024-00167-4.


Exploring the Complexity of the Human Respiratory Virome through an In Silico Analysis of Shotgun Metagenomic Data Retrieved from Public Repositories.

Conradie T, Caparros-Martin J, Egan S, Kicic A, Koks S, Stick S Viruses. 2024; 16(6).

PMID: 38932245 PMC: 11209621. DOI: 10.3390/v16060953.

References
1.
Coburn B, Wang P, Diaz Caballero J, Clark S, Brahma V, Donaldson S . Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015; 5:10241. PMC: 4431465. DOI: 10.1038/srep10241. View

2.
Sherrard L, Tunney M, Elborn J . Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet. 2014; 384(9944):703-13. DOI: 10.1016/S0140-6736(14)61137-5. View

3.
Whiteson K, Meinardi S, Lim Y, Schmieder R, Maughan H, Quinn R . Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. ISME J. 2014; 8(6):1247-58. PMC: 4030226. DOI: 10.1038/ismej.2013.229. View

4.
Rudkjobing V, Thomsen T, Alhede M, Kragh K, Nielsen P, Johansen U . The microorganisms in chronically infected end-stage and non-end-stage cystic fibrosis patients. FEMS Immunol Med Microbiol. 2012; 65(2):236-44. DOI: 10.1111/j.1574-695X.2011.00925.x. View

5.
Brown P, Pope C, Marsh R, Qin X, McNamara S, Gibson R . Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota. Ann Am Thorac Soc. 2014; 11(7):1049-55. PMC: 4214062. DOI: 10.1513/AnnalsATS.201311-383OC. View